(PRWEB) December 27, 2013
In August of 2012, the United States Judicial Panel on Multidistric Litigation denied plaintiffs' request to have all Lipitor cases consolidated before a single court. (MDL No. 2459). The panel indicated that although the Lipitor litigation was a clear candidate for centralization, there had not been enough cases filed to warrant the formation of a MDL. (MDL No. 2459 Order Denying Transfer).
More cases have since been filed and plaintiffs will again seek centralization January 2014 (MDL 2502).
The lawsuits allege Pfizer failed to warn woman of the of the possible risk of developing Type II diabetes as a result of taking the cholesterol lowering drug Lipitor.
The FDA required Pfizer and other statin manufacturers to update labels in early 2012 to warn of the possibility of increased blood sugar.
McSweeney / Langevin is currently advising woman who have taken Lipitor, Zocor and/or Crestor and subsequently developed Type II diabetes.
About McSweeney / Langevin
With the sole purpose of helping the injured, the personal injury law firm McSweeney / Langevin ensures victims and victims’ families are adequately compensated for wage loss, medical expenses and pain and suffering. While most firms have you speak with an “investigator” or “case manager,” McSweeney / Langevin connects people directly with one if its attorneys who will be handling your case. The firm handles personal injury cases related to dangerous/defective pharmaceutical drugs, dangerous/defective medical devices, and serious/catastrophic injury claims. All consultations are private. McSweeney / Langevin handles all cases on a contingent fee basis. For more information, visit http://www.westrikeback.com or call 1-800-888-4425.